JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

105.35 4.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

98.93

Max

106.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.9B

15B

Ankstesnė atidarymo kaina

101.24

Ankstesnė uždarymo kaina

105.35

Naujienos nuotaikos

By Acuity

50%

50%

144 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-09 17:25; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

2026-02-09 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

2026-02-09 23:43; UTC

Rinkos pokalbiai

Gold Falls on Possible Technical Correction -- Market Talk

2026-02-09 23:14; UTC

Rinkos pokalbiai

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

2026-02-09 22:29; UTC

Rinkos pokalbiai

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

2026-02-09 22:19; UTC

Rinkos pokalbiai

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

2026-02-09 22:08; UTC

Rinkos pokalbiai

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

2026-02-09 22:01; UTC

Uždarbis

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

2026-02-09 21:59; UTC

Uždarbis

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

2026-02-09 21:59; UTC

Uždarbis

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

2026-02-09 21:58; UTC

Uždarbis

Friedman Industries 3Q Sales $168M >FRD

2026-02-09 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-09 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-09 21:48; UTC

Uždarbis

Friedman Industries 3Q EPS 43c >FRD

2026-02-09 21:17; UTC

Uždarbis

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

2026-02-09 21:13; UTC

Rinkos pokalbiai

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

2026-02-09 21:04; UTC

Uždarbis

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

2026-02-09 20:30; UTC

Rinkos pokalbiai

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

2026-02-09 20:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

2026-02-09 19:42; UTC

Rinkos pokalbiai

Japan's Yield Curve Expected to Flatten -- Market Talk

2026-02-09 19:31; UTC

Rinkos pokalbiai

Nike Seen Regaining Relevance With Consumers -- Market Talk

2026-02-09 19:27; UTC

Rinkos pokalbiai

Gold Climbs Back Over $5,000/oz -- Market Talk

2026-02-09 19:05; UTC

Rinkos pokalbiai

Nike Returns to List of Hottest Brands -- Market Talk

2026-02-09 18:19; UTC

Rinkos pokalbiai

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

2026-02-09 17:41; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

2026-02-09 17:31; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

2026-02-09 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-09 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-09 17:17; UTC

Rinkos pokalbiai

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

2026-02-09 17:16; UTC

Uždarbis

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

26% į viršų

12 mėnesių prognozė

Vidutinis 128.33 USD  26%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

144 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat